CL2023003725A1 - Agentes aglutinantes biespecíficos que se unen a cldn18.2 y cd3 - Google Patents
Agentes aglutinantes biespecíficos que se unen a cldn18.2 y cd3Info
- Publication number
- CL2023003725A1 CL2023003725A1 CL2023003725A CL2023003725A CL2023003725A1 CL 2023003725 A1 CL2023003725 A1 CL 2023003725A1 CL 2023003725 A CL2023003725 A CL 2023003725A CL 2023003725 A CL2023003725 A CL 2023003725A CL 2023003725 A1 CL2023003725 A1 CL 2023003725A1
- Authority
- CL
- Chile
- Prior art keywords
- binding agents
- bind
- bispecific binding
- binding
- specificity
- Prior art date
Links
- 239000011230 binding agent Substances 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención proporciona agentes de unión que comprenden al menos dos dominios de unión, donde un primer dominio de unión tiene especificidad para CLDN18.2 y un segundo dominio de unión tiene especificidad para CD3, y métodos para el uso de estos agentes de unión o ácidos nucleicos que los codifican para el tratamiento del cáncer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2021/066141 WO2022262959A1 (en) | 2021-06-15 | 2021-06-15 | Bispecific binding agents binding to cldn18.2 and cd3 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2023003725A1 true CL2023003725A1 (es) | 2024-05-17 |
Family
ID=77519090
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2023003725A CL2023003725A1 (es) | 2021-06-15 | 2023-12-13 | Agentes aglutinantes biespecíficos que se unen a cldn18.2 y cd3 |
Country Status (13)
Country | Link |
---|---|
US (2) | US11739145B2 (es) |
EP (1) | EP4355428A1 (es) |
KR (1) | KR20240032847A (es) |
CN (1) | CN117858906A (es) |
AR (1) | AR126154A1 (es) |
AU (1) | AU2022292895A1 (es) |
BR (1) | BR112023026566A2 (es) |
CA (1) | CA3222300A1 (es) |
CL (1) | CL2023003725A1 (es) |
CO (1) | CO2023017378A2 (es) |
IL (1) | IL308072A (es) |
TW (1) | TW202317624A (es) |
WO (2) | WO2022262959A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024126457A1 (en) * | 2022-12-14 | 2024-06-20 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
WO2004035607A2 (en) | 2002-10-17 | 2004-04-29 | Genmab A/S | Human monoclonal antibodies against cd20 |
CA2548817A1 (en) | 2003-12-04 | 2005-06-23 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
US20090004213A1 (en) | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
CN104470949A (zh) | 2012-05-15 | 2015-03-25 | 百时美施贵宝公司 | 通过破坏pd-1/pd-l1信号传输的免疫治疗 |
EP2943511B1 (en) | 2013-01-14 | 2019-08-07 | Xencor, Inc. | Novel heterodimeric proteins |
IL252480B2 (en) * | 2014-11-26 | 2023-12-01 | Xencor Inc | Heterodimeric antibodies that bind CD3 and tumor antigens |
WO2018054484A1 (en) * | 2016-09-23 | 2018-03-29 | Biontech Ag | Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases |
CN111518214B (zh) * | 2019-02-03 | 2023-09-22 | 上海健信生物医药科技有限公司 | 靶向cldn18.2的双特异性抗体及其制备方法和应用 |
PE20211400A1 (es) | 2018-08-03 | 2021-07-27 | Amgen Res Munich Gmbh | Constructos de anticuerpos para cldn18.2 y cd3 |
US20230192903A1 (en) * | 2020-05-29 | 2023-06-22 | Wuhan Yzy Biopharma Co., Ltd. | Bispecific antibody against cldn18.2 and cd3 |
-
2021
- 2021-06-15 WO PCT/EP2021/066141 patent/WO2022262959A1/en active Application Filing
-
2022
- 2022-06-15 AU AU2022292895A patent/AU2022292895A1/en active Pending
- 2022-06-15 CN CN202280042413.9A patent/CN117858906A/zh active Pending
- 2022-06-15 BR BR112023026566A patent/BR112023026566A2/pt unknown
- 2022-06-15 KR KR1020247001571A patent/KR20240032847A/ko unknown
- 2022-06-15 AR ARP220101578A patent/AR126154A1/es unknown
- 2022-06-15 CA CA3222300A patent/CA3222300A1/en active Pending
- 2022-06-15 WO PCT/EP2022/066299 patent/WO2022263508A1/en active Application Filing
- 2022-06-15 IL IL308072A patent/IL308072A/en unknown
- 2022-06-15 EP EP22750661.5A patent/EP4355428A1/en active Pending
- 2022-06-15 TW TW111122151A patent/TW202317624A/zh unknown
- 2022-12-06 US US18/062,465 patent/US11739145B2/en active Active
-
2023
- 2023-07-05 US US18/347,361 patent/US20240018234A1/en active Pending
- 2023-12-13 CL CL2023003725A patent/CL2023003725A1/es unknown
- 2023-12-14 CO CONC2023/0017378A patent/CO2023017378A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CO2023017378A2 (es) | 2024-02-05 |
AR126154A1 (es) | 2023-09-13 |
US20230137677A1 (en) | 2023-05-04 |
CN117858906A (zh) | 2024-04-09 |
TW202317624A (zh) | 2023-05-01 |
US20240018234A1 (en) | 2024-01-18 |
JP2024520868A (ja) | 2024-05-24 |
IL308072A (en) | 2023-12-01 |
BR112023026566A2 (pt) | 2024-03-05 |
EP4355428A1 (en) | 2024-04-24 |
WO2022262959A1 (en) | 2022-12-22 |
CA3222300A1 (en) | 2022-12-22 |
WO2022263508A1 (en) | 2022-12-22 |
AU2022292895A1 (en) | 2024-01-04 |
US11739145B2 (en) | 2023-08-29 |
KR20240032847A (ko) | 2024-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019022515A2 (pt) | Agentes de anticorpo direcionados contra o gene 3 de ativação linfocitária (lag-3) e usos dos mesmos | |
CO2023017378A2 (es) | Agentes aglutinantes biespecíficos que se unen a cldn18.2 y cd3 | |
CL2020003031A1 (es) | Agentes aglutinantes del psma y usos de estos. | |
CL2018000108A1 (es) | Moléculas de anticuerpo que se unen a cd22 | |
ES2542853T3 (es) | Método para tratar miastenia grave | |
CL2019003520A1 (es) | Anticuerpos que se unen específicamente a pd-1 y procedimientos de uso. | |
BR112019008859A2 (pt) | anticorpos direcionados contra a morte programada 1 (pd-1) | |
BR112019002168A2 (pt) | anticorpos trivalentes bispecíficos ligantes a claudina6 ou claudina18.2 e cd3 para o tratamento de doenças cancerígenas que expressam claudina | |
AR111288A1 (es) | Anticuerpos anti-phf-tau y sus usos | |
CO2020013833A2 (es) | Anticuerpo anti-muerte programada-ligando 1 y su uso | |
AR117952A2 (es) | Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos mediante su uso | |
BR112021021645A2 (pt) | Anticorpos anti-hvem e uso dos mesmos. | |
CL2022001717A1 (es) | Anticuerpo anti-lilrb1 y usos del mismo | |
PE20230306A1 (es) | Anticuerpos que se dirigen a un complejo que comprende hla-i no clasico y neoantigeno y sus metodos de uso | |
CL2021001607A1 (es) | Anticuerpos anti-pmel17 y conjugados de los mismos | |
AR119677A1 (es) | Dominios de unión anti-cd38 | |
CL2022003390A1 (es) | Métodos para tratar o prevenir las infecciones de sars-cov-2 y covid-19 con anticuerpos antiglicoproteína de espiga de sars-cov-2. | |
CL2022002410A1 (es) | Terapia combinada de inhibidores axl/mer y pd-1/pd-l1. | |
BR112022001336A2 (pt) | Anticorpo biespecífico anti-her2/anti-4-1bb e uso do mesmo | |
MX2020003947A (es) | Anticuerpo anti-cd3 y composicion farmaceutica para el tratamiento del cancer que comprende el mismo. | |
EA201691414A1 (ru) | Антитела к матриксной металлопротеиназе 9 и способы их применения | |
BR112023020574A2 (pt) | Anticorpos biespecíficos alvejados a nkp46 e cd38 e métodos de uso dos mesmos | |
MX2020003806A (es) | Anticuerpos monoclonales de adn que se dirigen a ctla-4 para el tratamiento y prevención del cáncer. | |
BR112022011350A2 (pt) | Composições e métodos para tratamento e prevenção da influenza | |
BR112022002761A2 (pt) | Proteínas de ligação a 4-1bb e ox40 e composições e métodos relacionados, anticorpos contra 4-1bb, anticorpos contra ox40 |